Randomized Control Trial (RCT)

A randomized control trial (RCT) is a type of study design that involves randomly assigning participants to either an experimental group or a control group to measure the effectiveness of an intervention or treatment.

Randomized Controlled Trials (RCTs) are considered the “gold standard” in medical and health research due to their rigorous design.

Control Group

A control group consists of participants who do not receive any treatment or intervention but a placebo or reference treatment. The control participants serve as a comparison group.

Random allocation, not deliberate matching, keeps the control group comparable to the experimental group. That is the key mechanism. Assignment is left to chance.

As a result, age, gender, social class, ethnicity, and countless other characteristics end up balanced across both groups on average, including traits no researcher thought to measure. That is randomization’s real power.

This is what lets researchers attribute any later difference in outcome to the treatment itself. The two groups start out alike in every respect but one: the intervention. That is why scientists treat the RCT as the gold standard for clinical trials.

Random Allocation

Random allocation and random assignment are terms used interchangeably in the context of a randomized controlled trial (RCT).

Both refer to assigning participants to different groups in a study (such as a treatment group or a control group) in a way that is completely determined by chance.

The process of random assignment controls for confounding variables, ensuring differences between groups are due to chance alone.

Without randomization, researchers might consciously or subconsciously assign patients to a particular group for various reasons.

Several methods can be used for randomization in a Randomized Control Trial (RCT). Here are a few examples:

1. Simple Randomization: This is the simplest method, like flipping a coin. Each participant has an equal chance of being assigned to any group. This can be achieved using random number tables, computerized random number generators, or drawing lots or envelopes.
2. Block Randomization: In this method, participants are randomized within blocks, ensuring that each block has an equal number of participants in each group. This helps to balance the number of participants in each group at any given time during the study.
3. Stratified Randomization: This method is used when researchers want to ensure that certain subgroups of participants are equally represented in each group. Participants are divided into strata, or subgroups, based on characteristics like age or disease severity, and then randomized within these strata.
4. Cluster Randomization: In this method, groups of participants (like families or entire communities), rather than individuals, are randomized.
5. Adaptive Randomization: In this method, the probability of being assigned to each group changes based on the participants already assigned to each group. For example, if more participants have been assigned to the control group, new participants will have a higher probability of being assigned to the experimental group.

Computer software can generate random numbers or sequences that can be used to assign participants to groups in a simple randomization process.

For more complex methods like block, stratified, or adaptive randomization, computer algorithms can be used to consider the additional parameters and ensure that participants are assigned to groups appropriately.

This step also protects allocation concealment, a related safeguard. It works by hiding the upcoming assignment sequence, so no one recruiting participants can steer a particular person into a particular group.

Preventing that kind of foreknowledge helps avoid selection bias and protects the validity of the study results.

Blinding (Masking)

Blinding, or masking, means withholding the group assignments during the study. No one, neither participants nor researchers, is told who is in which group. The reason is simple: bias.

A blinded study keeps participants from knowing about their treatment, which avoids bias in the research. Any information that could influence them is withheld until the study is complete.

Blinding can extend beyond participants to anyone involved in the research, including data collectors, evaluators, technicians, and data analysts.

Good blinding matters. It can eliminate several experimental biases: expectation effects, observer bias, confirmation bias, researcher bias, and other distortions that creep in once people know the group assignments.

A double-blind study takes this further. Neither the participants nor the researchers know who is receiving the drug or the placebo.

Each participant is randomly assigned to one of the two groups when they enroll, and the medication looks identical either way.

Figure 1. Evidence-based medicine pyramid. Each level of the pyramid reflects the quality of the research designs at that level.

Higher levels mean higher-quality evidence, but fewer studies of that kind exist in the published literature. Randomized controlled trials sit near the top, so fewer of them get published than weaker designs.

Research Designs

The choice of design should be guided by the research question and the nature of the treatments being studied. Practical considerations, such as sample size and resources, and ethical considerations, such as ensuring participants have access to potentially beneficial treatments, matter too.

The goal is to select a design that answers the research question validly and reliably, while minimizing bias and confounds.

1. Between-participants randomized designs

Between-participant design involves randomly assigning participants to different treatment conditions. In its simplest form, it has two groups: an experimental group receiving the treatment and a control group.

With more than two levels, multiple treatment conditions are compared. The key feature is that each participant experiences only one condition.

This design allows for clear comparison between groups without worrying about order effects or carryover effects.

It’s particularly useful for treatments that have lasting impacts or when experiencing one condition might influence how participants respond to subsequent conditions.

Example

A study testing a new antidepressant medication might randomly assign 100 participants to either receive the new drug or a placebo.

The researchers would then compare depression scores between the two groups after a specified treatment period to determine if the new medication is more effective than the placebo.

Use this design when:

• You want to compare the effects of different treatments or interventions
• Carryover effects are likely (e.g., learning effects or lasting physiological changes)
• The treatment effect is expected to be permanent
• You have a large enough sample size to ensure groups are equivalent through randomization

2. Factorial designs

Factorial designs investigate the effects of two or more independent variables simultaneously. They allow researchers to study both main effects of each variable and interaction effects between variables. Interactions matter.

These can be between-participants (different groups for each combination of conditions), within-participants (all participants experience all conditions), or mixed (combining both approaches).

Factorial designs let researchers see how different factors combine to influence outcomes, a fuller picture than testing one variable at a time. That efficiency matters.

They’re also more efficient than running separate studies for each variable, since a single design can reveal interactions a simpler one would miss.

Example

A study examining exercise intensity (high vs. low) and diet type (high-protein vs. high-carb) on weight loss might use a 2×2 factorial design. This crosses the two variables to create four groups.

Participants would be randomly assigned to one of four groups: high-intensity exercise with high-protein diet, or high-intensity exercise with high-carb diet. The other two groups paired low-intensity exercise with either a high-protein or a high-carb diet.

Use this design when:

• You want to study the effects of multiple independent variables simultaneously
• You’re interested in potential interactions between variables
• You want to increase the efficiency of your study by testing multiple hypotheses at once

3. Cluster randomized designs

In cluster randomized trials, groups or “clusters” of participants are randomized to treatment conditions, rather than individuals.

This is often used when individual randomization is impractical or when the intervention is naturally applied at a group level.

It’s particularly useful in educational or community-based research where individual randomization might be disruptive or lead to treatment diffusion.

Example:

A study testing a new teaching method might randomize entire classrooms to either use the new method or continue with the standard curriculum.

The researchers would then compare student outcomes between the classrooms using the different methods, rather than randomizing individual students.

Use this design when:

• You have a smaller sample size available
• Individual differences are likely to be large
• The effects of the treatment are temporary
• You can effectively control for order and carryover effects

4. Within-participants (repeated measures) designs

In these designs, each participant experiences all treatment conditions, serving as their own control.

Within-participants designs are more statistically powerful as they control for individual differences. They require fewer participants, making them more efficient.

However, they’re only appropriate when the treatment effects are temporary and when you can effectively counterbalance to control for order effects.

Example

A study on the effects of caffeine on cognitive performance might have participants complete cognitive tests on three separate occasions. Each time, they would have consumed a different amount of caffeine: none, a low dose, or a high dose.

The order of these conditions would be counterbalanced across participants to control for order effects.

Use this design when:

• You have a smaller sample size available
• Individual differences are likely to be large
• The effects of the treatment are temporary
• You can effectively control for order and carryover effects

5. Crossover designs

Crossover designs are a specific type of within-participants design where participants receive different treatments in different time periods.

This allows each participant to serve as their own control and can be more efficient than between-participants designs.

Crossover designs combine the benefits of within-participants designs (increased power, control for individual differences) with the ability to compare different treatments.

They’re particularly useful in clinical trials. Each participant experiences every treatment, but the effects of one must never bleed into the next.

Example:

A study comparing two different pain medications might have participants use one medication for a month, then switch to the other medication for another month after a washout period.

Pain levels would be measured during both treatment periods, allowing for within-participant comparisons of the two medications’ effectiveness.

Use this design when:

• You want to compare the effects of different treatments within the same individuals
• The treatments have temporary effects with a known washout period
• You want to increase statistical power while using a smaller sample size
• You want to control for individual differences in response to treatment

Advantages

Prevents bias

In randomized control trials, participants must be randomly assigned to either the intervention group or the control group. Each individual has an equal chance of being placed in either group.

This is meant to prevent selection bias and allocation bias and achieve control over any confounding variables to provide an accurate comparison of the treatment being studied.

Because the distribution of characteristics of patients that could influence the outcome is randomly assigned between groups, any differences in outcome can be explained only by the treatment.

High statistical power

Because the participants are randomized, the characteristics between the two groups are balanced. If a significant difference in the primary outcome then appears, researchers can reasonably assume it reflects the intervention, not some other difference between the groups.

This warrants researchers to be confident that randomized control trials will have high statistical power compared to other types of study designs.

Blinding

Blinding also reduces bias by hiding group assignments from participants, researchers, or both (see Blinding above for single-blind, double-blind, and triple-blind designs). Even partial blinding, such as an outcome assessor who does not know the allocation, helps keep results honest.

Limitations

Costly and Timely

Some interventions require years or even decades to evaluate, rendering them expensive and time-consuming.

It might take an extended period of time before researchers can identify a drug’s effects or discover significant results.

Trials also need years of recruitment and follow-up. They also require substantial infrastructure for randomization, blinding, monitoring, and data management, and the population being studied can change while the trial is still running.

Requires large sample size

There must be enough participants in each group of a randomized control trial so researchers can detect any true differences or effects in outcomes between the groups.

Researchers cannot detect clinically important results if the sample size is too small.

That is one reason many important questions are simply never tested with an RCT: the scale required rules them out before a trial is ever designed.

Change in population over time

Because randomized control trials are longitudinal, it is almost inevitable that some participants will not complete the study. People drop out due to death, migration, non-compliance, or simply losing interest. That loss adds up.

This tendency is known as selective attrition, and it can threaten a trial’s statistical power. It also raises a subtler danger: people who drop out of a demanding treatment are often those doing worst. Simply excluding them would flatter the intervention.

There is a safeguard for this.

Researchers guard against it with intention-to-treat analysis: everyone stays in the group they were originally randomized to, even if they never finished the treatment. It sounds paradoxical to count people who dropped out. But excluding them is what would actually bias the result.

Ethics

Randomized control trials are not always practical or ethical, and such limitations can prevent researchers from conducting their studies.

For example, a treatment could be too invasive to justify testing on healthy volunteers. Giving some participants a placebo instead of a real drug could also deny them their normal course of treatment for a serious illness. Without ethical approval, a randomized control trial cannot proceed.

External Validity and Generalisability

Randomization gives an RCT strong internal validity: confidence that the intervention, not something else, produced the result. That strength can come at a cost. External validity, whether the finding generalizes beyond the trial, can suffer.

To keep a sample clean, an explanatory trial often excludes patients with other conditions, the very old, the very ill, or those taking other medications. This produces a tidy but unrepresentative sample.

A therapy that works in a pristine trial can still falter in messier, everyday practice. Researchers call this the efficacy-effectiveness gap.

Pragmatic trials restore some of that realism. They test the intervention under ordinary, real-world conditions. The trade-off is real: some of the tight control gets sacrificed along the way, and that is the price of realism.

Publication Bias and the Limits of RCT Evidence

An RCT is only as trustworthy as what gets published. Trials with a positive, significant result are more likely to see print than null ones. This is publication bias.

Within a published trial, the pattern can repeat. Outcomes that “worked” get emphasized. Pre-planned outcomes that did not are quietly dropped.

Some questions cannot ethically or practically go through an RCT at all: rare conditions, long-term population outcomes, or traits like age and trauma history that cannot be randomly assigned. Observational research remains essential here, not a lesser substitute.

Even where an RCT is possible, it is not the only tool worth trusting. It answers one question well: the average effect of a defined intervention in a defined population.

It says less about why an intervention works, or for whom, the kind of understanding mechanistic and qualitative research can supply.

Contemporary Research

Recent work on the RCT has shifted from defending the design to auditing it. Researchers now ask empirically how often trials are biased, by how much, and what actually fixes it.

Quantifying How Design Flaws Bias Results

Page and colleagues (2016) reviewed the accumulated “meta-epidemiological” literature: studies that compare effect sizes across many trials by methodological feature. They found one clear pattern. Trials with weak or unclear allocation concealment systematically exaggerate the treatment effect.

The bias is largest for subjective, self-reported outcomes. That is precisely the kind of measure psychology relies on most.

A similar pattern shows up within clinical psychology itself. Cuijpers and colleagues (2010) coded over a hundred psychotherapy trials for adult depression against eight quality criteria, including intention-to-treat analysis and blinded outcome assessors.

Trials meeting every criterion reported effect sizes less than a third the size of the lower-quality studies. The effects of psychotherapy were still real. They had simply been overestimated by shortcuts in study design.

Does Preregistration Change What Trials Find?

The clearest evidence that reform works comes from cardiology. It is a natural experiment in what happens when trials must declare their outcome in advance.

• Aim: To test whether the proportion of null results among large clinical trials increased once prospective registration became mandatory in 2000.
• Method: Kaplan and Irvin (2015) identified 55 large US cardiovascular trials from 1970 to 2012 and coded each as published before or after 2000, when registration on ClinicalTrials.gov became mandatory.
• Results: Before 2000, 17 of 30 trials (57%) reported a significant benefit; after 2000, only 2 of 25 (8%) did. The drop tracked registration, not comparator choice or industry funding.
• Conclusion: When researchers had to declare their outcome in advance, the flood of positive findings largely dried up. Many earlier “positive” trials likely reflected flexible, after-the-fact outcome selection rather than genuine effects.

This mirrors psychology’s own reckoning. When the Open Science Collaboration (2015) tried to replicate 100 published psychology studies, only around a third to a half produced a significant result the second time.

Fictitious Example

An example of an RCT would be a clinical trial comparing a drug’s effect or a new treatment on a select population.

The researchers would randomly assign participants to either the experimental group or the control group. They would then compare outcomes between those who received the drug or treatment and those who did not.

Real-life Examples

• Fabiano, G. A., Schatz, N. K., Merrill, B. M., Piscitello, J., Hayes, T. B., Jusko, M., Gnagy, E. M., Greiner, A. R., Tower, D., Boeckel, A., Gallo, R., Lupas, K., Gordon, C., Ramos, M., Sikov, J., Caron, S., & Pelham, W. E., Jr. (2025). A randomized, controlled trial to evaluate the efficacy of a daily report card intervention to enhance the efficacy of individualized education programs for children with attention-deficit/hyperactivity disorder. Journal of Consulting and Clinical Psychology, 93(7), 484–499.
• Preventing illicit drug use in adolescents: Long-term follow-up data from a randomized control trial of a school population (Botvin et al., 2000).
• A prospective randomized control trial comparing medical and surgical treatment for early pregnancy failure (Demetroulis et al., 2001).
• A randomized control trial to evaluate a paging system for people with traumatic brain injury (Wilson et al., 2005).
• Prehabilitation versus Rehabilitation: A Randomized Control Trial in Patients Undergoing Colorectal Resection for Cancer (Gillis et al., 2014).
• A Randomized Control Trial of Right-Heart Catheterization in Critically Ill Patients (Guyatt, 1991).
• Berry, R. B., Kryger, M. H., & Massie, C. A. (2011). A novel nasal excitatory positive airway pressure (EPAP) device for the treatment of obstructive sleep apnea: A randomized controlled trial. Sleep, 34, 479–485.
• Gloy, V. L., Briel, M., Bhatt, D. L., Kashyap, S. R., Schauer, P. R., Mingrone, G., . . . Nordmann, A. J. (2013, October 22). Bariatric surgery versus non-surgical treatment for obesity: A systematic review and meta-analysis of randomized controlled trials. BMJ, 347.
• Streeton, C., & Whelan, G. (2001). Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: A meta-analysis of randomized controlled trials. Alcohol and Alcoholism, 36 (6), 544–552.

History of the RCT: The Streptomycin Trial

Before 1948, claims that a treatment worked usually came from doctors comparing patients they had chosen to treat against those they had not. That method is wide open to exactly the confounding bias randomization was later built to solve.

The Medical Research Council’s trial changed that. Austin Bradford Hill, the statistician who designed it, insisted on a formal random allocation procedure specifically to remove that bias.

The trial almost universally credited as the first properly randomized controlled trial is the Medical Research Council’s 1948 test of streptomycin for tuberculosis, designed with Hill. It set the template.

• Aim: To test whether streptomycin, added to standard bed-rest treatment, improved recovery in acute pulmonary tuberculosis, using a design that removed the allocation bias that had undermined earlier treatment claims.
• Method: Just over a hundred tuberculosis patients were randomly allocated to streptomycin plus bed rest, or bed rest alone, with the schedule concealed from admitting clinicians. Outcomes were assessed over six months by assessors blind to each patient’s treatment.
• Results: The streptomycin group did substantially better: radiological improvement was far more common, and six-month mortality was markedly lower, roughly 7% versus 27%. The trial also reported a downside honestly, as streptomycin-resistant bacteria emerged rapidly.
• Conclusion: Streptomycin plus bed rest beat bed rest alone for tuberculosis. Combining random allocation, concealment, and blinded assessment showed a practical, defensible way to compare treatments without bias, and the trial became the template for the modern RCT.

Randomization was accepted as ethical here for a specific reason. Streptomycin was in genuinely scarce supply, so allocating it by lottery was arguably fairer than leaving the choice to physician preference.

That took real ethical thought.

That is an early, concrete example of clinical equipoise: genuine uncertainty about which treatment works better. It is the ethical condition every RCT still has to satisfy. That legacy still shapes practice.

The streptomycin trial’s design, random allocation combined with concealment and blinding, is still the template every RCT is judged against today.

It is also why the RCT sits near the top of the hierarchy of evidence for questions about whether a treatment actually works. That hierarchy places it above cohort studies, case-control studies, and expert opinion alone.

References

Akobeng, A.K., Understanding randomized controlled trials. Archives of Disease in Childhood, 2005; 90: 840-844.

Bell, C. C., Gibbons, R., & McKay, M. M. (2008). Building protective factors to offset sexually risky behaviors among black youths: a randomized control trial. Journal of the National Medical Association, 100 (8), 936-944.

Bhide, A., Shah, P. S., & Acharya, G. (2018). A simplified guide to randomized controlled trials. Acta obstetricia et gynecologica Scandinavica, 97 (4), 380-387.

Botvin, G. J., Griffin, K. W., Diaz, T., Scheier, L. M., Williams, C., & Epstein, J. A. (2000). Preventing illicit drug use in adolescents: Long-term follow-up data from a randomized control trial of a school population. Addictive Behaviors, 25 (5), 769-774.

Cuijpers, P., van Straten, A., Bohlmeijer, E., Hollon, S. D., & Andersson, G. (2010). The effects of psychotherapy for adult depression are overestimated: A meta-analysis of study quality and effect size. Psychological Medicine, 40 (2), 211-223. https://doi.org/10.1017/S0033291709006114

Demetroulis, C., Saridogan, E., Kunde, D., & Naftalin, A. A. (2001). A prospective randomized control trial comparing medical and surgical treatment for early pregnancy failure. Human Reproduction, 16 (2), 365-369.

Gillis, C., Li, C., Lee, L., Awasthi, R., Augustin, B., Gamsa, A., … & Carli, F. (2014). Prehabilitation versus rehabilitation: a randomized control trial in patients undergoing colorectal resection for cancer. Anesthesiology, 121 (5), 937-947.

Globas, C., Becker, C., Cerny, J., Lam, J. M., Lindemann, U., Forrester, L. W., … & Luft, A. R. (2012). Chronic stroke survivors benefit from high-intensity aerobic treadmill exercise: a randomized control trial.
Neurorehabilitation and Neural Repair, 26
(1), 85-95.

Guyatt, G. (1991). A randomized control trial of right-heart catheterization in critically ill patients. Journal of Intensive Care Medicine, 6 (2), 91-95.

Hróbjartsson, A., & Gøtzsche, P. C. (2001). Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. New England Journal of Medicine, 344 (21), 1594-1602. https://doi.org/10.1056/NEJM200105243442106

Kaplan, R. M., & Irvin, V. L. (2015). Likelihood of null effects of large NHLBI clinical trials has increased over time. PLoS ONE, 10 (8), e0132382. https://doi.org/10.1371/journal.pone.0132382

Medical Research Council. (1948). Streptomycin treatment of pulmonary tuberculosis: A Medical Research Council investigation. British Medical Journal, 2 (4582), 769-782.

MediLexicon International. (n.d.). Randomized controlled trials: Overview, benefits, and limitations. Medical News Today. Retrieved from https://www.medicalnewstoday.com/articles/280574#what-is-a-randomized-controlled-trial

Open Science Collaboration. (2015). Estimating the reproducibility of psychological science. Science, 349 (6251), aac4716. https://doi.org/10.1126/science.aac4716

Page, M. J., Higgins, J. P. T., Clayton, G., Sterne, J. A. C., Hróbjartsson, A., & Savović, J. (2016). Empirical evidence of study design biases in randomized trials: Systematic review of meta-epidemiological studies. PLoS ONE, 11 (7), e0159267. https://doi.org/10.1371/journal.pone.0159267

Schulz, K. F., Altman, D. G., & Moher, D. (2010). CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. BMJ, 340, c332. https://doi.org/10.1136/bmj.c332

Wilson, B. A., Emslie, H., Quirk, K., Evans, J., & Watson, P. (2005). A randomized control trial to evaluate a paging system for people with traumatic brain injury. Brain Injury, 19 (11), 891-894.